general

Apne 2 cancelled after Dharmendra’s demise confirms Anil Sharma: “Without Dharamji, it’s impossible to make the sequel”

The news of Dharmendra’s death has not only left a deep void for his fans, but it has also brought an abrupt end to one of Bollywood’s most nostalgic projects. Director Anil Sharma has confirmed that Apne 2 a film meant to unite three generations of the Deol family will now never be made. Dharmendra, 89, died on November 24 after battling prolonged illness. He had been discharged from Mumbai’s Breach Candy Hospital just days earlier and was being monitored at home when his condition worsened. Anil Sharma, who had been preparing to direct Apne 2, admitted that the film cannot go ahead now. Speaking to Hindustan Times, he said, “Apne to apno ke bina nahi ho sakti. Without Dharamji, it’s impossible to make the sequel. Everything was on track and the script was ready, but he left us. Some dreams remain unfulfilled. Without him, it’s not possible!”The sequel was planned as a continuation of the 2007 family drama Apne, with Dharmendra, Sunny Deol, Bobby Deol and Karan Deol leading the narrative. Despite being announced years ago, the film never began shooting. Sharma and Dharmendra shared a working relationship spanning multiple films, including Hukumat, Elaan-E-Jung, Farishtay, Tahalka, and Apne. Their reunion with Apne 2 was meant to be another emotional chapter in their partnership one that now remains unfinished. Dharmendra’s last film to release will now be Ikkis, directed by Sriram Raghavan and starring Agastya Nanda. The film arrives in cinemas on December 25, 2025, exactly a month after the actor’s passing. On Monday, the makers shared a tribute poster and wrote, “Fathers raise sons. Legends raise nations. Dharmendra ji, an emotional powerhouse as the father of a 21-year-old immortal soldier. One timeless legend brings us the story of another.”Prime Minister Narendra Modi on Monday condoled the veteran actor’s death, calling his passing “the end of an era in Indian cinema.” In a post on X, the Prime Minister described the legendary star as an iconic figure whose versatility and screen presence left a deep imprint on generations of filmgoers. He said Dharmendra brought “charm and depth” to every role, making him one of the most beloved actors in Indian film history.

general

INJ Price Prediction: Targeting $8.50-$9.00 Range Within 4 Weeks Despite Current Weakness

The post INJ Price Prediction: Targeting $8. 50-$9. 00 Range Within 4 Weeks Despite Current Weakness appeared com. Iris Coleman Nov 15, 2025 17: 40 Injective shows bullish MACD momentum despite -4. 32% decline. INJ price prediction suggests recovery to $8. 50+ if $6. 90 pivot holds, targeting analyst consensus of $8. 97. INJ Price Prediction: Recovery Rally Expected After Technical Reset Injective Protocol (INJ) presents an intriguing setup for traders as technical indicators suggest a potential bounce from current oversold levels. Despite trading at $6. 87 with a -4. 32% decline in the past 24 hours, several factors point toward a recovery rally that could push INJ toward the $8. 50-$9. 00 range within the next month. INJ Price Prediction Summary • INJ short-term target (1 week): $7. 80-$8. 20 (+13-19% from current levels) • Injective medium-term forecast (1 month): $8. 50-$9. 00 range targeting analyst consensus • Key level to break for bullish continuation: $7. 44 (SMA 20 resistance) • Critical support if bearish: $6. 02 immediate support, $6. 09 Bollinger lower band Recent Injective Price Predictions from Analysts The analyst community shows remarkable convergence in their Injective forecast, with recent predictions clustering around the $8. 00-$9. 00 range. AMB Crypto’s progressive INJ price prediction targets have steadily increased from $8. 23 on November 17th to $8. 97 by December 2nd, suggesting growing confidence in upward momentum. WalletInvestor’s more conservative $7. 54 INJ price target stands as the lone bearish outlier, based on historical price action showing potential downward pressure. However, the majority consensus points to a recovery toward the $8. 50+ zone, representing potential upside of 20-30% from current levels. The clustering of predictions around $8. 00-$9. 00 creates a compelling risk-reward scenario, especially with INJ trading significantly below these targets at $6. 87. INJ Technical Analysis: Setting Up for Recovery The Injective technical analysis reveals a classic oversold bounce setup developing. With RSI at 40. 04, INJ has moved from oversold territory into neutral ground, providing room for upward movement without immediately.

general

Polkadot (DOT) Slides 12% as Bears Break Key Support at $2.87

The post Polkadot (DOT) Slides 12% as Bears Break Key Support at $2. 87 appeared com. DOT$2. 5593 cracked under intense selling pressure Monday, dropping 12% to $2. 56 as institutional-sized orders broke critical support levels, according to CoinDesk Research’s technical analysis model. The model showed that the token posted extreme volatility, swinging from session highs of $2. 99 to $2. 56 lows. Bears dominated price action during early morning hours when massive volume spikes overwhelmed technical defenses. The session’s defining moment struck at 03: 00 UTC as exceptional selling pressure reached 5. 49 million tokens, more than double the 24-hour moving average, according to the model. This institutional-sized distribution event coincided with a decisive break below the $2. 87 support zone, according to the model. Technical Analysis: Primary support broke at $2. 76 following institutional selling cascade Critical resistance zone at $2. 80-$2. 82 represents next upside target Major resistance at $2. 87 breakdown level remains key reclaim threshold Session high of $2. 99 serves as ultimate resistance for bullish continuation Exceptional selling pressure of 5. 49 million tokens marked 106% above average Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk’s full AI Policy. Source:.